Inventor · disambiguated record
Thomas Schall
Also filed as: SCHALL THOMAS · SCHALL THOMAS J
48 granted patents·35 pending applications·395 citations·filing 1995–2023
98Inventor score
Top patents by PatentIndex Score
83 records- 0197US11045469B2Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor type 9 (CCR9) and anti-α4β7 integrin blocking antibodiesCHEMOCENTRYX INC·Filed 2020·Granted Jun 29, 2021·5 cites·18 claims
- 0295US10792360B1Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodiesCHEMOCENTRYX INC·Filed 2020·Granted Oct 6, 2020·6 cites·16 claims
- 0395US6559160B1Compounds and methods for modulating cxcr3 functionCHEMOCENTRYX INC·Filed 2000·Granted May 6, 2003·73 cites·22 claims
- 0494US7262204B2Modulation of CCR4 functionCHEMOCENTRYX INC·Filed 2003·Granted Aug 28, 2007·87 cites·18 claims
- 0592US11382915B2Treatment of focal segmental glomerulosclerosis with CCR2 antagonistsCHEMOCENTRYX INC·Filed 2020·Granted Jul 12, 2022·2 cites·20 claims
- 0691US11324736B2Method of Treating Focal Segmental GlomerulosclerosisCHEMOCENTRYX INC·Filed 2020·Granted May 10, 2022·2 cites·23 claims
- 0791US7335653B2Bis-aryl sulfonamidesCHEMOCENTRYX INC·Filed 2007·Granted Feb 26, 2008·9 cites·4 claims
- 0890US11304952B2Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitorCHEMOCENTRYX INC·Filed 2018·Granted Apr 19, 2022·11 cites·16 claims
- 0990US6699677B1Tethered ligands and methods of useCHEMOCENTRYX INC·Filed 2000·Granted Mar 2, 2004·31 cites·37 claims
- 1088US7227035B2Bis-aryl sulfonamidesCHEMOCENTRYX·Filed 2004·Granted Jun 5, 2007·30 cites·18 claims
- 1188US6723520B2Antibodies that bind chemokine teckSCHERING CORP·Filed 2002·Granted Apr 20, 2004·11 cites·22 claims
- 1286US10973809B2Method of treating focal segmental glomerulosclerosisCHEMOCENTRYX INC·Filed 2017·Granted Apr 13, 2021·4 cites·15 claims
- 1386US10758540B2Treatment of focal segmental glomerulosclerosis with CCR2 antagonistsCHEMOCENTRYX INC·Filed 2018·Granted Sep 1, 2020·4 cites·26 claims
- 1485US7279460B2Chemokine TECK polypeptidesSCHERING CORP·Filed 2004·Granted Oct 9, 2007·7 cites·7 claims
- 1584US11020394B2Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C—C chemokine receptor type 9 (CCR9) and anti-α4β7 integrin blocking antibodiesCHEMOCENTRYX INC·Filed 2019·Granted Jun 1, 2021·1 cites·8 claims
- 1683US10568870B2Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitorsCHEMOCENTRYX INC·Filed 2017·Granted Feb 25, 2020·2 cites·10 claims
- 1783US7585502B2Mammalian CX3C chemokine antibodiesSCHERING CORP·Filed 2008·Granted Sep 8, 2009·4 cites·19 claims
- 1883US6740324B2Methods and compositions useful for stimulating an immune responseCHEMOCENTRYX INC·Filed 2002·Granted May 25, 2004·10 cites·70 claims
- 1981US6512103B1Mammalian chemokine reagentsSCHERING CORP·Filed 1995·Granted Jan 28, 2003·32 cites·13 claims
- 2080US7678891B2Antibodies that bind CCX-CKR2CHEMOCENTRYX INC·Filed 2006·Granted Mar 16, 2010·3 cites·18 claims
- 2179US7785804B2Mammalian CX3C chemokine antibodiesSCHERING CORP·Filed 2009·Granted Aug 31, 2010·2 cites·23 claims
- 2279US6566503B2Mammalian CX3C chemokineSCHERING CORP·Filed 2001·Granted May 20, 2003·11 cites·5 claims
- 2377US7572600B2Enzymatic activities in chemokine-mediated inflammationCHEMOCENTRYX INC·Filed 2005·Granted Aug 11, 2009·3 cites·10 claims
- 2477US7276238B2Methods for using chemokine teckSCHERING CORP·Filed 2004·Granted Oct 2, 2007·2 cites·20 claims
- 2576US12194032B2Method of treating focal segmental glomerulosclerosisCHEMOCENTRYX INC·Filed 2022·Granted Jan 14, 2025·0 cites·20 claims
- 2675US2024100041A1Compositions and methods for treating inflammatory bowel disease using ccr9 inhibitor and anti-il-23 blocking antibodiesCHEMOCENTRYX INC·Filed 2023·Application pending·0 cites
- 2773US7253007B2Compositions and methods for detecting and treating diseases and conditions related to chemokine receptorsCHEMOCENTRYX INC·Filed 2003·Granted Aug 7, 2007·5 cites·14 claims
- 2872US2022296601A1Treatment of focal segmental glomerulosclerosis with ccr2 antagonistsCHEMOCENTRYX INC·Filed 2022·Application pending·0 cites
- 2972US2023105869A1C5aR INHIBITOR REDUCTION OF URINARY sCD163CHEMOCENTRYX INC·Filed 2022·Application pending·0 cites
- 3072US2021322410A1Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alpha4beta7 integrin blocking antibodiesCHEMOCENTRYX INC·Filed 2021·Application pending·0 cites
- 3170US11883391B2Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodiesCHEMOCENTRYX INC·Filed 2021·Granted Jan 30, 2024·0 cites·8 claims
- 3270US7442512B2Compositions and methods for detecting and treating diseases and conditions related to chemokine receptorsCHEMOCENTRYX INC·Filed 2002·Granted Oct 28, 2008·5 cites·22 claims
- 3370US2009191629A1Mammalian chemokine reagentsSCHERING CORP·Filed 2009·Application pending·0 cites
- 3469US6992084B2Compounds and methods for modulating CXCR3 functionCHEMOCENTRYX INC·Filed 2002·Granted Jan 31, 2006·3 cites·22 claims
- 3569US6835547B1Methods for identifying modulators of CCX CKR activityCHEMOCENTRYX INC·Filed 2000·Granted Dec 28, 2004·7 cites·34 claims
- 3667US7025968B2CMV vaccinesCHEMOCENTRYX INC·Filed 2001·Granted Apr 11, 2006·7 cites·34 claims
- 3766US2023023075A1Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitorCHEMOCENTRYX INC·Filed 2022·Application pending·0 cites
- 3866US2008044835A1Mammalian chemokine reagentsWANG WEI·Filed 2007·Application pending·0 cites
- 3965US6821998B2Arylamines as inhibitors of chemokine binding to US28CHEMOCENTRYX INC·Filed 2002·Granted Nov 23, 2004·2 cites·12 claims
- 4063US7777009B2Compositions for detecting and treating diseases and conditions related to chemokine receptorsCHEMOCENTRYX INC·Filed 2007·Granted Aug 17, 2010·0 cites·3 claims
- 4162US7871619B2Compositions and methods for detecting and treating diseases and conditions related to chemokine receptorsCHEMOCENTRYX INC·Filed 2004·Granted Jan 18, 2011·1 cites·10 claims
- 4262US7132508B2Mammalian chemokine reagentsSCHERING CORP·Filed 2002·Granted Nov 7, 2006·0 cites·8 claims
- 4361US11744822B2Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitorsCHEMOCENTRYX INC·Filed 2020·Granted Sep 5, 2023·0 cites·10 claims
- 4461US7108990B2Chemokine receptorCHEMOCENTRYX INC·Filed 2004·Granted Sep 19, 2006·0 cites·14 claims
- 4561US2019134020A1C5aR INHIBITOR REDUCTION OF URINARY sCD163CHEMOCENTRYX INC·Filed 2018·Application pending·0 cites
- 4660US8343492B2Method for blocking binding of CX3C chemokines using CX3C chemokine antibodiesSCHERING CORP·Filed 2012·Granted Jan 1, 2013·0 cites·6 claims
- 4760US7741519B2Bis-aryl sulfonamidesCHEMOCENTRYX INC·Filed 2008·Granted Jun 22, 2010·0 cites·20 claims
- 4860US2010144720A1Inhibitors of human tumor-expressed ccxckr2CHEMOCENTRYX INC·Filed 2009·Application pending·0 cites
- 4958US11844790B2Methods of treating hidradenitis suppurativaCHEMOCENTRYX INC·Filed 2021·Granted Dec 19, 2023·0 cites·8 claims
- 5058US2022257580A1Treatment of c3 glomerulopathy using a c5a inhibitorCHEMOCENTRYX INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 83 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Thomas Schall files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →